Apimeds Pharmaceuticals US (APUS) Total Current Liabilities (2023 - 2025)

Apimeds Pharmaceuticals US's Total Current Liabilities history runs 3 years deep, the most recent figure standing at $10.7 million for Q4 2025.

• Quarterly Total Current Liabilities rose 945.21% year-over-year to $10.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.7 million (up 945.21% YoY) and the FY2025 annual result came in at $10.7 million, up 945.21% from the prior year.
• Total Current Liabilities was $10.7 million for Q4 2025 at Apimeds Pharmaceuticals US, up from $1.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $10.7 million in Q4 2025 and bottomed at $123316.0 in Q4 2023.
• A 3-year average of $2.6 million and a median of $1.1 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 730.66% — and 2025, when it surged 945.21%.
• Apimeds Pharmaceuticals US's Total Current Liabilities stood at $123316.0 in 2023, then surged by 730.66% to $1.0 million in 2024, then jumped by 945.21% to $10.7 million in 2025.
• Business Quant data shows APUS's Total Current Liabilities at $10.7 million in Q4 2025, $1.1 million in Q3 2025, and $809002.0 in Q2 2025.